Invest now

Windlas Biotech share price

Balanced risk
  • 37%Low risk
  • 37%Moderate risk
  • 37%Balanced risk
  • 37%High risk
  • 37%Extreme risk
Analyse on
AI
  • ₹956.15(-3.67%)
    October 9, 2026 14:07:20 PM IST
    • NSE
    • BSE
  • Vol : 81.78 K (NSE + BSE)
    Last 20 day avg : 93.07 K
Windlas Biotech is trading -3.67% lower at Rs 956.15 as compared to its last closing price. Windlas Biotech has been trading in the price range of 1,006.00 & 947.90. Windlas Biotech has given 24.72% in this year & -9.14% in the last 5 days. Windlas Biotech has TTM P/E ratio 27.22 as compared to the sector P/E of 46.88.The company posted a net profit of 17.65 Crores in its last quarter.Listed peers of Windlas Biotech include Sun Pharmaceutical Industries (0.79%), Divi's Laboratories (-0.43%), Torrent Pharmaceuticals (-0.89%).The Mutual Fund holding in Windlas Biotech was at 5.76% in 30 Jun 2026. The MF holding has decreased from the last quarter. The FII holding in Windlas Biotech was at 2.04% in 30 Jun 2026. The FII holding has increased from the last quarter.
  • Overview
  • Financials
  • Forecast
  • Technical Analysis
  • Peers
  • Shareholding
  • About the company
  • FAQ

Overview

  • 1 D
  • 5 D
  • 1 M
  • 3 M
  • 6 M
  • 1 Y
  • 5 Y
  • MAX
Loading...
Screen on
Try Now
Key Metrics

Updated on 09 Oct 2026, 02:14 PM IST

  • Beta
    Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
    0.54
    Low volatility
  • Debt To Equity
    The debt-to-equity ratio, indicating a company's financial leverage.
    0.06
    Higher than industry
  • Dividend Yield
    Annual dividends as a percentage of the stock price.
    0.62
    Lower than industry
  • P/B
    The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
    3.71
    Higher than historical values
  • P/E
    Price-to-earnings ratio based on trailing 12-month earnings
    32.80
    Higher than historical values
  • PEG Ratio
    The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
    1.99
    Indicates Fair Valuation
Price range
Day Range
Lowest
947.90
Highest
1,006.00
52 week range
Lowest
699.35
Highest
1,181.00
Windlas Biotech News
Windlas Biotech Peers
Return Comparison
Peers Comparison
Names
Price%ChangeMarket CapP/EP/BDividend YieldDebt to Equity
Sun Pharmaceutical Industries		1,766.400.794,23,808.5438.405.550.830.47
Divi's Laboratories		9,348.85-0.432,48,182.5973.3211.480.410.03
Torrent Pharmaceuticals		4,633.40-0.891,76,233.3472.7319.220.80141.16
Cipla		1,307.100.161,05,595.1727.573.330.921.11
Zydus Lifesciences		1,119.000.341,11,620.6821.194.240.0914.22
Mutual Fund Ownership
View all
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Growth
NA
  • Amount Invested (Cr.) 78.25
  • % of AUM 1.42
UTI Healthcare Fund Regular Plan Growth
NA
  • Amount Invested (Cr.) 13.80
  • % of AUM 1.30
ICICI Prudential Smallcap Fund Growth
2/5
  • Amount Invested (Cr.) 33.50
  • % of AUM 0.41
ICICI Prudential Smallcap Fund Institutional Growth
3/5
  • Amount Invested (Cr.) 33.50
  • % of AUM 0.41
Bandhan BSE Healthcare Index Fund Regular Growth
NA
  • Amount Invested (Cr.) 0.02
  • % of AUM 0.06
Windlas Biotech Corporate Actions
View all
  • Board Meetings
  • AGM
  • Dividends
  • Bonus
  • Split
  • Rights
Meeting DatePurpose
2026-08-10Quarterly Results
2026-05-21Audited Results & Final Dividend
2026-04-17Buy Back of Shares
2026-02-05Quarterly Results
2025-11-06Quarterly Results
About the company Windlas Biotech
  • IndustryBiotechnology & Drugs
  • ISININE0H5O01029
  • BSE Code543329
  • NSE CodeWINDLAS
Windlas Biotech Limited is a domestic pharmaceutical formulations contract development and manufacturing organization (CDMO). Its portfolio of CDMO solutions includes product development, licensing, and commercial manufacturing of complex drugs and dosage forms. Its product development and manufacturing capabilities in complex generic products by developing products, including alternate dosages, such as, medicated mouth sprays; coating technologies, including, pellet coating using bottom spray, API coating, pH dependent coating and nanosized crystals; nutraceuticals dosages, including, biscuits, protein powder, supplements, chocolate bars and malt based foods, and ayurvedic products, such as wellness products, hair oils and cough syrups. Its four fungible, Schedule-M compliant OSD/OLD manufacturing facilities are located in Dehradun, Uttarakhand, India. It specializes in manufacturing formulations, solid pharmaceutical dosage forms, liquid pharmaceutical dosage forms and injectables.
  • Management Info
Management info for Windlas Biotech is currently unavailable
Please check back later.
Windlas Biotech Share Price FAQs

Windlas Biotech is trading at 956.15 as on Fri Oct 09 2026 08:37:20. This is -3.67% lower as compared to its previous closing price of 992.55.

The market capitalization of Windlas Biotech is 2031.87 Cr as on Fri Oct 09 2026 08:37:20.

The 52 wk high for Windlas Biotech is 1181.00 whereas the 52 wk low is 699.35

Windlas Biotech can be analyzed on the following key metrics -

  • TTM P/E: 27.22
  • Sector P/E: 46.88
  • Dividend Yield: 0.64%
  • D/E ratio: -

Windlas Biotech reported a net profit of 66.46 Cr in 2026.

The Mutual Fund Shareholding was 5.76% at the end of 30 Jun 2026.

Quick Links
EQUITY QUICK LINKS
Windlas Biotech QUICK LINKS
FROM MARKETS
RELATED LINKS
Quarterly Results
Home/Market/Market Stats/  Windlas Biotech share price
✕

Wait for it…

Log in to our website to save your bookmarks. It'll just take a moment.

✕

Wait for it…

Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.